复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

圣诞节休市 12-24 12:08:24

20.520

-0.220

-1.06%

最高20.740	最低20.340	成交量121.70万
今开20.520	昨收20.740	日振幅1.93%
总市值545.63亿	流通市值111.01亿	总股本26.59亿
成交额2,496万	换手率0.22%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.52,"timestamp":1766549304003,"preClose":20.74,"halted":0,"volume":1216963,"delay":0,"floatShares":540971500,"shares":2659000000,"eps":1.15086124461103,"marketStatus":"圣诞节休市","change":-0.22,"latestTime":"12-24 12:08:24","open":20.52,"high":20.74,"low":20.34,"amount":24957898,"amplitude":0.019286,"askPrice":20.52,"askSize":1000,"bidPrice":20.42,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":1.3734128040841085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":20.74,"dividendRate":0.017258,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.798054909268429,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.11,"timestamp":1766559600000,"preClose":27.09,"halted":0,"volume":8106400,"delay":0,"premium":"-31.78"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2593768604","title":"复星医药：募投项目结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2593768604","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593768604?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:05","pubTimestamp":1766570739,"startTime":"0","endTime":"0","summary":"南财智讯12月24日电，复星医药公告，截至2025年12月22日，公司2022年非公开发行募集资金已全部按承诺投入相关募投项目，专户中的募集资金（包括利息收入）已全部使用完毕，本次发行涉及的募投项目结项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600840925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","02196","BK0183","BK0187","BK0188","BK1191","BK1593","BK0028","BK0060","600196","BK1515","BK0012","BK0196","BK0175","BK0096"],"gpt_icon":0},{"id":"2593413090","title":"复星医药：公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413090","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593413090?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:08","pubTimestamp":1766498900,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，复星医药在互动平台回答投资者提问时表示，公司业务布局主要涵盖制药、医疗器械与医学诊断、医疗健康服务三个板块，其中药品、器械及诊断产品的主要市场包括中国、美国、欧洲及新兴市场在内的多个国家和地区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599787764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLV","BK1583","LABU","BK0175","BK1515","BK0012","BK1222","159760","BK0196","09996","XBI","BK1593","BK4581","09997","BK0239","BK0060","600196","BK1100","BK0096","BK0188","BK1191","BK0183","BK0187","BK4585","BK1574","BK4588","159883","02196","01477","BK0028"],"gpt_icon":0},{"id":"2593459642","title":"复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459642","media":"中访网数据","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459642?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1574","BK1515","02196","BK1593","BK1191"],"gpt_icon":0},{"id":"2593145964","title":"每日卖空追踪 | 复星医药 12月22日卖空量成交1.5万股，卖空比例为0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593145964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593145964?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392229,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月22日，跌1.61%，卖空量成交1.5万股，较上一交易日减少95.69%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163433a6c09b6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163433a6c09b6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2593459625","title":"复星医药12月22日主力净流出355.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459625","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459625?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:16","pubTimestamp":1766391367,"startTime":"0","endTime":"0","summary":"12月22日, 复星医药股价跌1.61%，报收20.74元，成交金额4432.1万元，换手率0.39%，振幅2.28%，量比0.32。复星医药今日主力资金净流出355.9万元，上一交易日主力净流入272.3万元。该股近5个交易日下跌7.25%，主力资金累计净流出2813.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出242.5万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162427a4698853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162427a4698853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1191","BK1515"],"gpt_icon":0},{"id":"2593431863","title":"复星万邦阿昔替尼片启动生物等效性试验 适应症为进展期肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593431863","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593431863?lang=zh_cn&edition=full","pubTime":"2025-12-22 12:03","pubTimestamp":1766376180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，复星万邦（江苏）医药集团有限公司的阿昔替尼片在健康试验参与者中的随机、开放、两制剂、两序列、四周期、完全重复交叉设计、空腹和餐后状态下的生物等效性试验已启动。阿昔替尼片为化学药物，适应症为既往接受过一种酪氨酸激酶抑制剂或细胞因子治疗失败的进展期肾细胞癌的成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222132557a6bfea3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222132557a6bfea3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00656","BK1230","02196"],"gpt_icon":0},{"id":"2593125369","title":"复星高管回应！为何巨额收购“971”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593125369","media":"药械VIP","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593125369?lang=zh_cn&edition=full","pubTime":"2025-12-21 10:23","pubTimestamp":1766283783,"startTime":"0","endTime":"0","summary":"12月15日，复星医药公告，拟出资约14.12亿元，收购绿谷（上海）医药科技有限公司51%的股权。2024年，971在中国卖出200多万盒。但各界对971的质疑从未间断。2025年，因绿谷医药未完成上市后确证性临床研究，国家药监局没有重新批准971的上市申请，该药停产。12月15日晚间，复星医药高管在电话会上表示：根据现有临床证据，他们看好971的疗效与前景。接下来，复星医药将推动971的上市后确证性临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221111029a4652ebd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251221111029a4652ebd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1191","02196"],"gpt_icon":0},{"id":"2592577131","title":"复星医药：控股子公司药品获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592577131","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592577131?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:20","pubTimestamp":1766136033,"startTime":"0","endTime":"0","summary":"南方财经12月19日电，复星医药(600196.SH)公告称，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司获美国FDA批准开展HLX18（重组抗PD-1人源化单克隆抗体注射液）用于治疗多种实体瘤的I期临床试验。复宏汉霖拟于条件具备后于美国开展该药品的I期临床试验。HLX18是复星医药自主研发的纳武利尤单抗生物类似药，拟用于多种癌症的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596838564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0188","BK0183","BK1593","BK1515","BK1191","BK0060","BK0239","BK0187","BK0012","600196","BK0096","BK0175","BK0196","02196"],"gpt_icon":0},{"id":"2592999481","title":"复星医药双线突围：14亿押注争议药物，全球合作对冲研发风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2592999481","media":"投资时报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592999481?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:52","pubTimestamp":1766134346,"startTime":"0","endTime":"0","summary":"评估报告显示，截至2025年9月30日，绿谷医药股东全部权益的评估值为16.74亿元。为了应对挑战，复星医药正持续加大向创新药的转型力度。就在市场将焦点投向绿谷医药的同时，复星医药的全球布局仍在提速。12月18日，复星医药宣布其控股子公司复星医药产业与美国Clavis Bio公司签订《合作及选择权协议》，双方将共同选定靶点推进临床前药物开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219165312a45f4c19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219165312a45f4c19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","BK1515","02196"],"gpt_icon":0},{"id":"2592619994","title":"每日卖空追踪 | 复星医药 12月19日卖空量成交14.25万股，卖空比例为3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592619994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592619994?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133027,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月19日，涨2.23%，卖空量成交14.25万股，较上一交易日增加22.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163425a45f3590&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163425a45f3590&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2592819915","title":"复星医药12月19日主力净流入272.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819915","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592819915?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132145,"startTime":"0","endTime":"0","summary":"12月19日, 复星医药股价涨2.23%，报收21.08元，成交金额9571.9万元，换手率0.84%，振幅3.30%，量比0.68。复星医药今日主力资金净流入272.3万元，上一交易日主力净流出7.3万元。该股近5个交易日下跌5.33%，主力资金累计净流出2684.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入312.9万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161951a45f22d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161951a45f22d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2592513686","title":"【券商聚焦】交银国际：临近年末 续看好新BD交易集中落地机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513686?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:20","pubTimestamp":1766107245,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周多项超10亿美元的BD交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，该机构继续看好新BD交易集中落地机会。展望2026 年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971853","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU0588546209.SGD","LU1303224171.USD","BK1191","LU0634319403.HKD","02228","LU1115378108.SGD","IE00B5MMRT66.SGD","09926","02367","BK1197","BK1583","LU0417516902.SGD","LU1251922891.USD","01530","LU0348825331.USD","LU1720050803.USD","LU0348784397.USD","01789","06160","01099","BK1500","IE00B543WZ88.USD","LU0348783233.USD","LU2328871848.SGD","BK1588","LU0417516738.SGD","LU0348766576.USD","BK1147","LU2476274720.SGD","02196","03329","HK0000165453.HKD","LU2399975544.HKD","02268","03933","BK1585","LU2778985437.USD","LU0561508036.HKD","BK1617","BK1593","SG9999014674.SGD","LU1770034418.SGD","09688","LU0348735423.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516571.SGD","LU2476274308.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2592199155","title":"复星一周两次落子汉正街 补缺“外滩中心”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199155","media":"观点","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199155?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:31","pubTimestamp":1766100660,"startTime":"0","endTime":"0","summary":"一周之内，两场落槌，复星在汉正街约投入26亿元。本次土拍最受关注的焦点，无疑是复星集团在汉正街的再度加码。据市场分析，复星并非简单的规模扩张，而是基于“复星外滩中心”项目整体规划调整后的资产确权。三年后的2017年1月，复星进一步扩大版图，斥资130.1亿元竞得汉正街东片核心地块，正式确立了“复星外滩中心”百万方大盘格局，并计划在此引入金融蜂巢产业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219131040a45e77f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219131040a45e77f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02196","BK1191","BK1593"],"gpt_icon":0},{"id":"2592906229","title":"官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906229","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592906229?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:55","pubTimestamp":1766062500,"startTime":"0","endTime":"0","summary":"　　多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批“吃螃蟹”的保险机构。一则“官宣！复星联合健康保险9款医疗险覆盖商保创新药！”复星联合健康保险的官宣无疑令业内欣喜。　　复星联合健康保险“悔棋”动作的背后，与首次推出的《商业健康保险创新药品目录》不无关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfrcf8430514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1061106388.HKD","LU0107464264.USD","LU1066053197.SGD","LU1267930573.SGD","LU2552382132.HKD","IE00B1BXHZ80.USD","IE00BFXG1179.USD","LU2089984988.USD","LU2362541513.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0738911758.USD","LU2552382215.SGD","LU2244417387.USD","BK4581","LU0211327993.USD","LU2357305700.SGD","LU2089283258.USD","LU0187121727.USD","LU0211326755.USD","LU1732800096.USD","LU2028103732.USD","LU1064131342.USD","LU1720051017.SGD","IE00BJJMRX11.SGD","LU1267930730.SGD","SG9999001176.SGD","BK4588","IE00B19Z3581.USD","LU0203345920.USD","LU0345770308.USD","LU1854104046.USD","SG9999017495.SGD","LU0128525929.USD","LU0079474960.USD","LU0310800965.SGD","LU1267930227.SGD","LU1791710400.SGD","LU2324357040.USD","LU0029864427.USD","LU1670627923.USD","LU2491049909.HKD","IE00BKPKM429.USD","LU1069347547.HKD","IE0002141913.USD","LU1291159041.SGD","LU1989771016.USD","LU2089284900.SGD","LU1066051225.USD","LU1074936037.SGD","LU0058720904.USD","LU1057294990.SGD","LU0965509101.SGD","LU1551013342.USD","LU1496350502.SGD","IE00BFSS8Q28.SGD","LU0882574055.USD","LU0861579265.USD","LU0661504455.SGD","LU2347655156.SGD","LU2360032135.SGD","IE00BN29S564.USD","LU1037948541.HKD","IE00BJT1NW94.SGD","LU1323610961.USD","LU2361044865.SGD","SGXZ51526630.SGD","BK1161","IE00B19Z9505.USD","LU2087625088.SGD","LU2461242641.AUD","SG9999014914.USD","LU2362541273.HKD","BK4532","600196","LU1023059063.AUD","LU2023251221.USD","LU0310800379.SGD","LU0342679015.USD","LU1814569148.SGD","LU0211328371.USD","LU0048584097.USD","LU0965509010.AUD","LU0053666078.USD","LU0965508806.USD","LU1506573853.SGD","LU1934455277.USD","LU0456855351.SGD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU0949170772.SGD","LU0553294199.USD","LU2361044949.HKD","LU0545039389.USD","LU2468319806.SGD","BK4566","SG9999002232.USD","LU0820562030.AUD","SG9999018865.SGD","IE00B19Z8X17.USD","IE00BJJMRY28.SGD","LU0198837287.USD","LU1674673428.USD","LU1791710582.SGD","IE00B894F039.SGD","IE0004445239.USD","LU0097036916.USD","SG9999014898.SGD","LU0417517546.SGD","LU0011850046.USD","LU0122379950.USD","LU0965509283.SGD","LU1261432733.SGD","BK4533","LU0354030511.USD","IE00B19Z9P08.USD","SG9999002224.SGD","LU2279689827.SGD","LU0820561818.USD","IE00BZ1G4Q59.USD","LU0432979614.USD","LU0912757837.SGD","IE0005OL40V9.USD","LU0672654240.SGD","LU1551013425.SGD","LU0353189763.USD","LU0234572021.USD","LU1934455194.USD","IE00BZ9MQY76.HKD","LU0345770993.USD","LU1670628061.USD","SG9999018857.SGD","LU0823416689.USD","LU0266013472.USD","IE0004445015.USD","IE00B775H168.HKD","LU1119994496.HKD","LU0795875086.SGD","LU0256863811.USD","LU2361045086.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0976567544.SGD","SGXZ57979304.SGD","IE00B7KXQ091.USD","LU1778281490.HKD","LU0158827948.USD","LU1934455863.HKD","LU0316494557.USD","LU0708995401.HKD","LU0496365809.HKD","LU2491050154.USD","IE00B4JS1V06.HKD","LU0077335932.USD","LU0109391861.USD","LU0203347892.USD","LU0320765059.SGD","LU0787776722.HKD","LU1003077747.HKD","LU0158827781.USD","LU2133065610.SGD","LU2211815571.USD","IE00BFSS7M15.SGD","LU0354030438.USD","LU1035773651.USD","BK4534","SGXZ99366536.SGD","LU2125154778.USD","LU0708994859.HKD","IE00BWXC8680.SGD","LU1674673691.USD","SGXZ31699556.SGD","IE0009355771.USD","LU0238689110.USD","LU2362540622.SGD","LU1267930490.SGD","LU0557290698.USD","LU0683600562.USD","SG9999014880.SGD","LU1153585028.USD","IE00B7SZLL34.SGD","LU2264538146.SGD","LU0128525689.USD","LU2125154935.USD","IE00B4R5TH58.HKD","LU2242649171.HKD","SG9999001176.USD","LU1914381329.SGD","BK4154","LU1548497426.USD","SG9999013999.USD","BK4585","LU0310799852.SGD","LU0528227936.USD","LU0795875169.SGD","IE0002270589.USD","LU1720051108.HKD","02196","LU1084165304.USD","LU1854103824.USD","LU1718418525.SGD","LU1732799900.SGD","LU0251132253.USD","IE000M9KFDE8.USD","IE00BKVL7J92.USD","LU0211326839.USD","LU0943347566.SGD","LU0820561909.HKD","LU0149725797.USD","LU1066051811.HKD","LU0052756011.USD","LU1066051498.USD","LU0094547139.USD","LU2552382058.USD","LU2236285917.USD","LU1037948897.HKD","LU0289739699.SGD","LU1983299246.USD","LU2271345857.HKD","LU1988902786.USD","BK1574","LU2111349929.HKD","LU2112291526.USD","SG9999014906.USD","LU2491050071.SGD","SGXZ81514606.USD","IE00B1XK9C88.USD","IE00B19Z8W00.USD","LU0114720955.EUR","LU0353189680.USD","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2592972970","title":"复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972970","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592972970?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:29","pubTimestamp":1766053787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点并推进针对获选靶点化合物的临床前开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0188","BK0196","BK0187","BK0060","BK1191","600196","BK1593","02196","BK0175","BK0012","BK0096","BK1515","BK0028","BK0239"],"gpt_icon":0},{"id":"2592970730","title":"每日卖空追踪 | 复星医药 12月18日卖空量成交5.45万股，卖空比例为1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592970730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592970730?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046626,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月18日，涨0.29%，卖空量成交5.45万股，较上一交易日减少65.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163420a45aa2e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163420a45aa2e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","02196","BK1191"],"gpt_icon":0},{"id":"2592973957","title":"诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973957","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973957?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027230,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。诺和诺德在美国的“高增长”依赖的是Wegovy的爆发式放量，而非整体产品线扩张。诺和诺德虽凭Wegovy实现高增长，却因技术代差、市场饱和与研发滞后被迫战略收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2242644610.SGD","02196","BK1589","HK0000165453.HKD","LU0455707207.USD","LU2488822045.USD","LU1969619763.USD","01801","03933","LU2097828631.EUR","LU2097828557.USD","01276","LU2097828714.EUR","BK1583","BK1161","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2592097943","title":"AD药物销售额有望超过140亿美元，这家头部药企今年多次布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592097943","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592097943?lang=zh_cn&edition=full","pubTime":"2025-12-18 10:35","pubTimestamp":1766025331,"startTime":"0","endTime":"0","summary":"据悉，当前，各大药企正在持续加码AD药物研发。目前，Adel-Y01正在美国食品药品监督管理局批准的研究性新药申请下，进行全球1期临床试验。有报告显示，2025年，全球AD药物销售额为86.7亿美元，预计到2034年，该药物销售额有望达到140.6亿美元。在国内市场，头部药企也在积极引进AD药物，如复星医药2025年12月15日宣布拟出资约14.12亿元控股收购绿谷医药，将获得其用于治疗轻度至中度阿尔茨海默病核心药品甘露特钠胶囊。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103950a4595745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103950a4595745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2592979144","title":"复星高管回应！为何巨额收购“971”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979144","media":"药通社","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592979144?lang=zh_cn&edition=full","pubTime":"2025-12-18 10:28","pubTimestamp":1766024898,"startTime":"0","endTime":"0","summary":"12月15日，复星医药公告，拟出资约14.12亿元，收购绿谷（上海）医药科技有限公司51%的股权。2024年，971在中国卖出200多万盒。但各界对971的质疑从未间断。2025年，因绿谷医药未完成上市后确证性临床研究，国家药监局没有重新批准971的上市申请，该药停产。12月15日晚间，复星医药高管在电话会上表示：根据现有临床证据，他们看好971的疗效与前景。接下来，复星医药将推动971的上市后确证性临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103529a6b06376&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103529a6b06376&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2592979432","title":"三元股份股东复星创泓减持0.62%股份，一致行动人持股比例降至17.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979432","media":"中访网数据","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592979432?lang=zh_cn&edition=full","pubTime":"2025-12-18 08:02","pubTimestamp":1766016145,"startTime":"0","endTime":"0","summary":"核心事件为复星创泓因自身资金需求，于2025年12月15日至16日期间，通过上海证券交易所集中竞价交易系统减持了公司股份9,364,200股，占公司总股本的比例约为0.62%。本次减持后，复星创泓的持股数量由约5,666.16万股减少至约4,729.74万股，持股比例由3.77%降至3.15%。权益变动后，复星创泓与平闰投资合计持有三元股份约26,657.45万股，占公司总股本的比例由18.37%下降至17.75%，本次变动触及持股比例减少1%的披露刻度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218081248a458c758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218081248a458c758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":-0.0284},{"period":"3month","weight":-0.2144},{"period":"6month","weight":0.2898},{"period":"1year","weight":0.4923},{"period":"ytd","weight":0.4817}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051338},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.018426}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}